Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance of $9.5 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $1.48 per share was 5.8% above analysts’ consensus estimates.
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
It’s easy to understand why income investors are interested in Pfizer. With a current yield of 7.1%, it’s one of the highest-yielding stocks in the S&P 500. Let’s dig into the dividend and see whether it’s in any better shape than the stock.
Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations and national security concerns.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
(BPT) - Content sponsored and provided by Pfizer. Ashley partnered with Pfizer to share her experience living with moderate to severe rheumatoid arthritis (RA).
U.S. stock futures are down Wednesday morning, despite major averages ending up on Tuesday, and the S&P 500 and Dow Jones notching their sixth-straight day in the green, the longest streak for the indexes in months.
